Search

Your search keyword '"Eriksson, Jan W"' showing total 711 results
Start Over Author "Eriksson, Jan W"
711 results on '"Eriksson, Jan W"'

201. Cortisol Axis Regulation is Altered in Healthy Relatives of Type 2 Diabetes Patients

Author

LINDMARK, STINA A, OLSSON, TOMMY, TUFVESSON, MAGNUS, and ERIKSSON, JAN W

Subjects
Diabetes -- Research, Health
Abstract

To elucidate potential neuroendocrine mechanisms of early insulin resistance in type 2 diabetes we studied 15 young, healthy individuals with either two first-degree or one first-degree plus two second-degree relatives [...]

Published
1999

202. Low Cellular IRS 1 Gene and Protein Expression Predict Insulin Resistance and Type 2 Diabetes

Author

CARVALHO, EUGENIA, JANSSON, PER-ANDERS, AXELSEN, METTE, ERIKSSON, JAN W, HUANG, XUDON, GROOP, LEIF, RONDINONE, CRISTINA, SJOSTROM, LARS, and SMITH, ULF P

Subjects
Diabetes -- Research, Health
Abstract

No cellular markers of individuals at risk for insulin resistance and type 2 diabetes have been identified. We recently reported that IRS-1 protein expression and associated PI3-kinase activity were markedly [...]

Published
1999

203. Abstract 17736: Cardiomyocyte Specific Loss of Diacylglycerol Acyl Transferase 1 (Dgat1) Reproduces the Abnormalities in Lipids Found in Severe Heart Failure

Author

Trent, Chad M, primary, Liu, Li, additional, Fang, Xiang, additional, Son, Ni-Huiping, additional, Jiang, Hongfeng, additional, Blaner, William S, additional, Yin, Yu-Xin, additional, Farese, Robert V, additional, Homma, Shunichi, additional, Turnbull, Andrew V, additional, Eriksson, Jan W, additional, Hu, Shi-Lian, additional, Ginsberg, Henry N, additional, Huang, Li-Shin, additional, and Goldberg, Ira J, additional

Published
2014
Full Text
View/download PDF

204. Cardiomyocyte-specific Loss of Diacylglycerol Acyltransferase 1 (DGAT1) Reproduces the Abnormalities in Lipids Found in Severe Heart Failure

Author

Liu, Li, primary, Trent, Chad M., additional, Fang, Xiang, additional, Son, Ni-Huiping, additional, Jiang, HongFeng, additional, Blaner, William S., additional, Hu, Yunying, additional, Yin, Yu-Xin, additional, Farese, Robert V., additional, Homma, Shunichi, additional, Turnbull, Andrew V., additional, Eriksson, Jan W., additional, Hu, Shi-Lian, additional, Ginsberg, Henry N., additional, Huang, Li-Shin, additional, and Goldberg, Ira J., additional

Published
2014
Full Text
View/download PDF

207. Microdialysis and proteomics of subcutaneous interstitial fluid reveals increased galectin-1 in type 2 diabetes patients.

Author

Fryk, Emanuel, Sundelin, Jeanna Perman, Strindberg, Lena, Pereira, Maria J., Federici, Massimo, Marx, Nikolaus, Nyström, Fredrik H., Schmelz, Martin, Svensson, Per-Arne, Eriksson, Jan W., Borén, Jan, and Jansson, Per-Anders

Subjects
MICRODIALYSIS, PROTEOMICS, SUBCUTANEOUS infusions, EXTRACELLULAR fluid, GALECTINS, TYPE 2 diabetes treatment, ADIPOKINETIC hormone
Abstract

Objective To identify a potential therapeutic target for type 2 diabetes by comparing the subcutaneous interstitial fluid from type 2 diabetes patients and healthy men. Methods Proteomics was performed on the interstitial fluid of subcutaneous adipose tissue obtained by microdialysis from 7 type 2 diabetes patients and 8 healthy participants. 851 proteins were detected, of which 36 (including galectin-1) showed significantly altered expression in type 2 diabetes. We also measured galectin-1 expression in: (1) adipocytes isolated from adipose tissue biopsies from these participants; (2) subcutaneous adipose tissue of 24 obese participants before, during and after 16 weeks on a very low calorie diet (VLCD); and (3) adipocytes isolated from 6 healthy young participants after 4 weeks on a diet and lifestyle intervention to promote weight gain. We also determined the effect of galectin-1 on glucose uptake in human adipose tissue. Results Galectin-1 protein levels were elevated in subcutaneous dialysates from type 2 diabetes compared with healthy controls (p < 0.05). In agreement, galectin-1 mRNA expression was increased in adipocytes from the type 2 diabetes patients (p < 0.05). Furthermore, galectin-1 mRNA expression was decreased in adipose tissue after VLCD (p < 0.05) and increased by overfeeding (p < 0.05). Co-incubation of isolated human adipocytes with galectin-1 reduced glucose uptake (p < 0.05) but this was independent of the insulin signal. Conclusion Proteomics of the interstitial fluid in subcutaneous adipose tissue in vivo identified a novel adipokine, galectin-1, with a potential role in the pathophysiology of type 2 diabetes. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

208. Design and Optimization of Pyrazinecarboxamide-Based Inhibitors of Diacylglycerol Acyltransferase 1 (DGAT1) Leading to a Clinical Candidate Dimethylpyrazinecarboxamide Phenylcyclohexylacetic Acid (AZD7687)

Author

Barlind, Jonas G., primary, Bauer, Udo A., additional, Birch, Alan M., additional, Birtles, Susan, additional, Buckett, Linda K., additional, Butlin, Roger J., additional, Davies, Robert D. M., additional, Eriksson, Jan W., additional, Hammond, Clare D., additional, Hovland, Ragnar, additional, Johannesson, Petra, additional, Johansson, Magnus J., additional, Kemmitt, Paul D., additional, Lindmark, Bo T., additional, Morentin Gutierrez, Pablo, additional, Noeske, Tobias A., additional, Nordin, Andreas, additional, O’Donnell, Charles J., additional, Petersson, Annika U., additional, Redzic, Alma, additional, Turnbull, Andrew V., additional, and Vinblad, Johanna, additional

Published
2012
Full Text
View/download PDF

211. Effects of hyperinsulinemia on lipoprotein lipase, angiopoietin-like protein 4, and glycosylphosphatidylinositol-anchored high-density lipoprotein binding protein 1 in subjects with and without type 2 diabetes mellitus

Author

Ruge, Toralph, primary, Sukonina, Valentina, additional, Kroupa, Olessia, additional, Makoveichuk, Elena, additional, Lundgren, Magdalena, additional, Svensson, Maria K., additional, Olivecrona, Gunilla, additional, and Eriksson, Jan W., additional

Published
2012
Full Text
View/download PDF

214. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis

Author

Birkeland, Kåre I, Jørgensen, Marit E, Carstensen, Bendix, Persson, Frederik, Gulseth, Hanne L, Thuresson, Marcus, Fenici, Peter, Nathanson, David, Nyström, Thomas, Eriksson, Jan W, Bodegård, Johan, and Norhammar, Anna

Abstract

In patients with type 2 diabetes and a high cardiovascular risk profile, the sodium-glucose co-transporter-2 (SGLT2) inhibitors empagliflozin and canagliflozin have been shown to lower cardiovascular morbidity and mortality. Using real-world data from clinical practice, we aimed to compare cardiovascular mortality and morbidity in new users of SGLT2 inhibitors versus new users of other glucose-lowering drugs, in a population with a broad cardiovascular risk profile.

Published
2017
Full Text
View/download PDF

215. DGAT1 deficiency decreases PPAR expression and does not lead to lipotoxicity in cardiac and skeletal muscle

Author

Liu, Li, primary, Yu, Shuiqing, additional, Khan, Raffay S., additional, Ables, Gene P., additional, Bharadwaj, Kalyani G., additional, Hu, Yunying, additional, Huggins, Lesley A., additional, Eriksson, Jan W., additional, Buckett, Linda K., additional, Turnbull, Andrew V., additional, Ginsberg, Henry N., additional, Blaner, William S., additional, Huang, Li-Shin, additional, and Goldberg, Ira J., additional

Published
2011
Full Text
View/download PDF

223. A 24-Week, Multicenter, Open-Label, Randomized Study to Compare Changes in Glucose Metabolism in Patients With Schizophrenia Receiving Treatment With Olanzapine, Quetiapine, or Risperidone

Author

Newcomer, John W., primary, Ratner, Robert E., additional, Eriksson, Jan W., additional, Emsley, Robin, additional, Meulien, Didier, additional, Miller, Frank, additional, Leonova-Edlund, Julia, additional, Leong, Ronald W., additional, and Brecher, Martin, additional

Published
2009
Full Text
View/download PDF

226. Hydrochlorothiazide, but not Candesartan, Aggravates Insulin Resistance and Causes Visceral and Hepatic Fat Accumulation

Author

Eriksson, Jan W., primary, Jansson, Per-Anders, additional, Carlberg, Bo, additional, Hägg, Anders, additional, Kurland, Lisa, additional, Svensson, Maria K., additional, Ahlström, Håkan, additional, Ström, Conny, additional, Lönn, Lars, additional, Öjbrandt, Kristina, additional, Johansson, Lars, additional, and Lind, Lars, additional

Published
2008
Full Text
View/download PDF

229. Early changes in glomerular size selectivity in young adults with type 1 diabetes and retinopathy. Results from the Diabetes Incidence Study in Sweden

Author

Torffvit, Ole, primary, Eriksson, Jan W., additional, Henricsson, Marianne, additional, Sundkvist, Göran, additional, Arnqvist, Hans J., additional, Blohmé, Göran, additional, Bolinder, Jan, additional, Nyström, Lennarth, additional, Östman, Jan, additional, and Svensson, Maria, additional

Published
2007
Full Text
View/download PDF

233. Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers

Author

Kalani, Majid, primary, Silveira, Angela, additional, Blombäck, Margareta, additional, Apelqvist, Jan, additional, Eliasson, Björn, additional, Eriksson, Jan W., additional, Fagrell, Bengt, additional, Torffvit, Ole, additional, Hamsten, Anders, additional, and Jörneskog, Gun, additional

Published
2007
Full Text
View/download PDF

234. Positron emission tomography ligand [11C]5-hydroxy-tryptophan can be used as a surrogate marker for the human endocrine pancreas.

Author

Eriksson, Olof, Espes, Daniel, Selvaraju, Ram K, Jansson, Emma, Antoni, Gunnar, Sörensen, Jens, Lubberink, Mark, Biglarnia, Ali-Reza, Eriksson, Jan W, Sundin, Anders, Ahlström, Håkan, Eriksson, Barbro, Johansson, Lars, Carlsson, Per-Ola, and Korsgren, Olle

Abstract

In humans, a well-developed serotonin system is localized to the pancreatic islets while being absent in exocrine pancreas. Assessment of pancreatic serotonin biosynthesis could therefore be used to estimate the human endocrine pancreas. Proof of concept was tested in a prospective clinical trial by comparisons of type 1 diabetic (T1D) patients, with extensive reduction of β-cells, with healthy volunteers (HVs). C-peptide-negative (i.e., insulin-deficient) T1D subjects (n = 10) and HVs (n = 9) underwent dynamic positron emission tomography with the radiolabeled serotonin precursor [(11)C]5-hydroxy-tryptophan ([(11)C]5-HTP). A significant accumulation of [(11)C]5-HTP was obtained in the pancreas of the HVs, with large interindividual variation. A substantial and highly significant reduction (66%) in the pancreatic uptake of [(11)C]5-HTP in T1D subjects was observed, and this was most evident in the corpus and caudal regions of the pancreas where β-cells normally are the major constituent of the islets. [(11)C]5-HTP retention in the pancreas was reduced in T1D compared with nondiabetic subjects. Accumulation of [(11)C]5-HTP in the pancreas of both HVs and subjects with T1D was in agreement with previously reported morphological observations on the β-cell volume, implying that [(11)C]5-HTP retention is a useful noninvasive surrogate marker for the human endocrine pancreas. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

235. Positron Emission Tomography Ligand [11C]5-Hydroxy-Tryptophan Can Be Used as a Surrogate Marker for the Human Endocrine Pancreas.

Author

Eriksson, Olof, Espes, Daniel, Selvaraju, Ram K., Jansson, Emma, Antoni, Gunnar, Sörensen, Jens, Lubberink, Mark, Biglarnia, Ali-Reza, Eriksson, Jan W., Sundin, Anders, Ahlström, Håkan, Eriksson, Barbro, Johansson, Lars, Carlsson, Per-Ola, and Korsgren, Olle

Subjects
DIABETES, ISLANDS of Langerhans, SEROTONIN, PANCREATIC acinar cells, POSITRON emission tomography, PANCREAS
Abstract

In humans, a well-developed serotonin system is localized to the pancreatic islets while being absent in exocrine pancreas. Assessment of pancreatic serotonin biosynthesis could therefore be used to estimate the human endocrine pancreas. Proof of concept was tested in a prospective clinical trial by comparisons of type 1 diabetic (T1D) patients, with extensive reduction of β-cells, with healthy volunteers (HVs). C-peptide-negative (i.e., insulin-deficient) T1D subjects (n = 10) and HVs (n = 9) underwent dynamic positron emission tomography with the radiolabeled serotonin precursor [11C]5-hydroxy-tryptophan ([11C]5-HTP). A significant accumulation of [11C]5-HTP was obtained in the pancreas of the HVs, with large interindividual variation. A substantial and highly significant reduction (66%) in the pancreatic uptake of [11C]5-HTP in T1D subjects was observed, and this was most evident in the corpus and caudal regions of the pancreas where β-cells normally are the major constituent of the islets. [11C]5-HTP retention in the pancreas was reduced in T1D compared with nondiabetic subjects. Accumulation of [11C]5-HTP in the pancreas of both HVs and subjects with T1D was in agreement with previously reported morphological observations on the β-cell volume, implying that [11C]5-HTP retention is a useful noninvasive surrogate marker for the human endocrine pancreas. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

240. Organ-specific metabolic pathways distinguish prediabetes, type 2 diabetes, and normal tissues

Author

Diamanti, Klev, Cavalli, Marco, Pereira, Maria J., Pan, Gang, Castillejo-López, Casimiro, Kumar, Chanchal, Mundt, Filip, Komorowski, Jan, Deshmukh, Atul S., Mann, Matthias, Korsgren, Olle, Eriksson, Jan W., and Wadelius, Claes

Abstract

Environmental and genetic factors cause defects in pancreatic islets driving type 2 diabetes (T2D) together with the progression of multi-tissue insulin resistance. Mass spectrometry proteomics on samples from five key metabolic tissues of a cross-sectional cohort of 43 multi-organ donors provides deep coverage of their proteomes. Enrichment analysis of Gene Ontology terms provides a tissue-specific map of altered biological processes across healthy, prediabetes (PD), and T2D subjects. We find widespread alterations in several relevant biological pathways, including increase in hemostasis in pancreatic islets of PD, increase in the complement cascade in liver and pancreatic islets of PD, and elevation in cholesterol biosynthesis in liver of T2D. Our findings point to inflammatory, immune, and vascular alterations in pancreatic islets in PD that are hypotheses to be tested for potential contributions to hormonal perturbations such as impaired insulin and increased glucagon production. This multi-tissue proteomic map suggests tissue-specific metabolic dysregulations in T2D.

Published
2022
Full Text
View/download PDF

242. FKBP5 expression in human adipose tissue increases following dexamethasone exposure and is associated with insulin resistance.

Author

Pereira, Maria J., Palming, Jenny, Svensson, Maria K., Rizell, Magnus, Dalenbäck, Jan, Hammar, Mårten, Fall, Tove, Sidibeh, Cherno O., Svensson, Per-Arne, and Eriksson, Jan W.

Subjects
GENE expression, ADIPOSE tissues, DEXAMETHASONE, INSULIN resistance, GLUCOCORTICOIDS, PHENOTYPES
Abstract

Objective To study effects of dexamethasone on gene expression in human adipose tissue aiming to identify potential novel mechanisms for glucocorticoid-induced insulin resistance. Materials/methods Subcutaneous and omental adipose tissue, obtained from non-diabetic donors (10 M/15 F; age: 28-60 years; BMI: 20.7-30.6 kg/m²), was incubated with or without dexamethasone (0.003-3 μmol/L) for 24 h. Gene expression was assessed by microarray and real time-PCR and protein expression by immunoblotting. Results FKBP5 (FK506-binding protein 5) and CNR1 (cannabinoid receptor 1) were the most responsive genes to dexamethasone in both subcutaneous and omental adipose tissue (~ 7-fold). Dexamethasone increased FKBP5 gene and protein expression in a dose-dependent manner in both depots. The gene product, FKBP51 protein, was 10-fold higher in the omental than in the subcutaneous depot, whereas the mRNA levels were similar. Higher FKBP5 gene expression in omental adipose tissue was associated with reduced insulin effects on glucose uptake in both depots. Furthermore, FKBP5 gene expression in subcutaneous adipose tissue was positively correlated with serum insulin, HOMA-IR and subcutaneous adipocyte diameter and negatively with plasma HDL-cholesterol. FKBP5 SNPs were found to be associated with type 2 diabetes and diabetes-related phenotypes in large population-based samples. Conclusions Dexamethasone exposure promotes expression of FKBP5 in adipose tissue, a gene that may be implicated in glucocorticoid-induced insulin resistance. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

243. Short and long term in vivo effects of Cyclosporine A and Sirolimus on genes and proteins involved in lipid metabolism in Wistar rats.

Author

Lopes, Patrícia C., Fuhrmann, Amelia, Sereno, José, Espinoza, Daniel O., Pereira, Maria João, Eriksson, Jan W., Reis, Flávio, and Carvalho, Eugenia

Subjects
CYCLOSPORINE, RAPAMYCIN, LIPID metabolism, LABORATORY rats, DYSLIPIDEMIA, IMMUNOSUPPRESSIVE agents, TRANSPLANTATION immunology, PROTEIN expression, GENE expression, LIPOLYSIS
Abstract

Abstract: Objective: Cyclosporine A (CsA) and sirolimus (SRL) are immunosuppressive agents (IA) associated with new onset diabetes after transplantation and dyslipidemia. We aim to evaluate the molecular effects of CsA (5mg/kg/day) and SRL (1mg/kg/day) treatment for 3 and 9weeks on lipid metabolism, in Wistar rats. Materials/Methods: Lipolysis was evaluated in isolated adipocytes, while triglycerides (TG) and non-esterified fatty acid (NEFA) were measured in serum. Gene and protein expression involved in lipid metabolism was assessed in adipose tissue and liver. Results: CsA and SRL treatments of rats for 3 and 9weeks increased isoproterenol-stimulated lipolysis by 5–9 fold and 4–6 fold in isolated adipocytes, respectively. While CsA increased adipocyte weight and diameter, as well as NEFA and TG levels in circulation after 9weeks, SRL treatment caused ectopic deposition of TG in the liver after 3weeks. Moreover, ACC1 and FAS protein expression was increased after 3weeks (>100%, p<0.01), while HSL was increased after 9weeks of CsA treatment. On the other hand, SRL decreased the expression of lipogenic genes, including ACC1 (50%, p<0.05), lipin1 (25%, p<0.05), PPAR-γ (42%, p<0.05) and SCD1 (80%, p<0.001) in adipose tissue, after 3weeks of treatment. Conclusion: The effects of both IAs on expression of lipolytic and lipogenic genes suggest that these agents influence lipid metabolism, thus contributing to the dyslipidemia observed during immunosuppressive therapy. [Copyright &y& Elsevier]

Published
2014
Full Text
View/download PDF

245. Response of multiple hormones to glucose and arginine challenge in T2DM after gastric bypass

Author

Fanni, Giovanni, Katsogiannos, Petros, Nandi Jui, Bipasha, Sundbom, Magnus, Hetty, Susanne, Pereira, Maria J, and Eriksson, Jan W

Abstract

In patients with type 2 diabetes mellitus (T2DM), Roux-en-Y gastric bypass (RYGB) leads to beneficial metabolic adaptations, including enhanced incretin secretion, beta-cell function, and systemic insulin sensitivity. We explored the impact of RYGB on pituitary, pancreatic, gut hormones, and cortisol responses to parenteral and enteral nutrient stimulation in patients with obesity and T2DM with repeated sampling up to 2 years after intervention.We performed exploratorypost hocanalyses in a previously reported randomized trial. Levels of adrenocorticotropic hormone (ACTH), cortisol, growth hormone (GH), glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic peptide (GIP), peptide YY (PYY), ACTH, insulin, and glucagon were measured in 13 patients with T2DM and obesity at four different visits: before and 4, 24, and 104 weeks after RYGB; and in three sequential conditions on the same day: fasting, intravenous arginine challenge, and OGTT.RYGB surprisingly induced a rise in ACTH, cortisol, and GH levels upon an oral glucose load, together with enhanced GLP-1 and PYY responses. Fasting and post-arginine GH levels were higher after RYGB, whereas insulin, glucagon, GLP-1, GIP, and cortisol were lower. These endocrine adaptations were seen as early as 4 weeks after surgery and were maintained for up to 2 years.These findings indicate adaptations of glucose sensing mechanisms and responses in multiple endocrine organs after RYGB, involving the gut, pancreatic islets, the pituitary gland, the adrenals, and the brain.

Published
2022
Full Text
View/download PDF

248. SHORT COMMUNICATION

Author

Samuelsson, Pär, primary, Blohmé, Göran, additional, Fowelin, Jesper, additional, and Eriksson, Jan W, additional

Published
1996
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results